Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Published on August 12, 2014 at 8:08 AM · No Comments

Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that its SYN-005 for the treatment of Pertussis will be highlighted at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9, in Washington D.C.

Synthetic Biologics' academic collaborator, Jennifer Maynard, Ph.D., of The University of Texas at Austin's McKetta Department of Chemical Engineering will present Synthetic Biologics' SYN-005 monoclonal antibody (mAb) combination for the treatment of Pertussis in an oral presentation scheduled for Sunday, September 7, at 9:45am Eastern Time in Room 209A as part of the "Neonatal Infections and the Case for Maternal Immunization" session.

Title: Rational Design of Antibody Cocktails to Treat Disease Caused by Bordetellae
Authors: M. Kaleko, A. Nguyen, E. Wagner, J. Laber, L. Goodfield, W. Smallridge, E. T. Harvill, R. F. Wolf, J. C. Papin, J. A. Maynard

"We are pleased to have Dr. Maynard showcase the research supporting the clinical development of SYN-005 amongst esteemed academic peers, and the infectious disease field's foremost leaders at ICAAC, a conference with high academic standards and commitment to providing an overview of the state of infection control and prevention on a global scale," stated Jeffrey Riley, Chief Executive Officer of Synthetic Biologics. "This scientific presentation is timely, as we continue to advance our innovative Pertussis program toward clinical-stage development in early 2015."

Source:

Synthetic Biologics, Inc.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
OncoSynergy's OS2966 receives FDA orphan drug designation for treatment of glioblastoma